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ABSTRACT
In the randomized, placebo‐controlled FREEDOM study of women aged 60 to 90 years with postmenopausal osteoporosis, treatment
with denosumab once every 6 months for 36 months significantly reduced hip and new vertebral fracture risk by 40% and 68%,
respectively. To gain further insight into this efficacy, we performed a nonlinear finite element analysis (FEA) of hip and spine
quantitative computed tomography (QCT) scans to estimate hip and spine strength in a subset of FREEDOM subjects (n¼ 48 placebo;
n¼ 51 denosumab) at baseline, 12, 24, and 36 months. We found that, compared with baseline, the finite element estimates of hip
strength increased from 12 months (5.3%; p< 0.0001) and through 36 months (8.6%; p< 0.0001) in the denosumab group. For the
placebo group, hip strength did not change at 12 months and decreased at 36 months (–5.6%; p< 0.0001). Similar changes were
observed at the spine: strength increased by 18.2% at 36 months for the denosumab group (p< 0.0001) and decreased by –4.2% for
the placebo group (p¼ 0.002). At 36 months, hip and spine strength increased for the denosumab group compared with the placebo
group by 14.3% (p< 0.0001) and 22.4% (p< 0.0001), respectively. Further analysis of the finite elementmodels indicated that strength
associated with the trabecular bone was lost at the hip and spine in the placebo group, whereas strength associated with both the
trabecular and cortical bone improved in the denosumab group. In conclusion, treatment with denosumab increased hip and spine
strength as estimated by FEA of QCT scans compared with both baseline and placebo owing to positive treatment effects in both the
trabecular and cortical bone compartments. These findings provide insight into the mechanism by which denosumab reduces
fracture risk for postmenopausal women with osteoporosis. © 2014 The Authors. Journal of Bone and Mineral Research published by
Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research. This is an open access article under the terms
of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in anymedium, provided
the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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Introduction
Denosumab (Prolia
1, Amgen Inc., Thousand Oaks, CA, USA) is
a fully human monoclonal antibody that inhibits receptor
activator of NF‐kB ligand (RANKL), a key modulator of osteoclast
formation, function, and survival.(1–4) In the phase 3 Fracture
Reduction Evaluation of Denosumab in Osteoporosis Every
6 Months (FREEDOM) study of 7808 postmenopausal women
with osteoporosis, aged between 60 and 90 years, denosumab
treatment reduced the risk of hip and new vertebral fractures
over 36 months compared with placebo by 40% and 68%,
respectively.(5) The fracture efficacy in the overall FREEDOM
population was associated with significant differences from
baseline to month 36 between denosumab and placebo in areal
bone mineral density (BMD) at the total hip and lumbar spine of
6.4% and 8.8%, respectively,(6) and rapid and marked reductions
in markers of bone resorption with an attenuation of the
reduction at the end of each 6‐month dosing interval.(5,7) Despite
the insight gained from the changes in BMD and bone turnover
markers, it remains unclear to what extent denosumab altered
hip or spine strength compared with baseline and placebo, and
the extent that denosumab modified bone strength in the
trabecular and cortical compartments, both of which are relevant
to understanding mechanisms of fracture protection.
Because directly measuring the strength of any bone in a living
human subject is not feasible, an alternative and FDA‐approved
approach to monitor treatment effects is to noninvasively
estimate changes in strength using finite element analysis (FEA)
of quantitative computed tomography (QCT) scans. Consistently
validated for assessment of whole‐bone strength in various
cadaver studies,(8–16) FEA of hip and spine QCT scans has been
shown to predict new incident hip(17–19) and spine(16) fractures
and to differentiate those with or without prevalent spine(20–23)
and general fractures.(24) FEA has also been used to study aging
effects in hip strength,(25) estimate changes in hip(26–29) and
spine(28,30–33) strength in response to various treatments as well as
space flight,(34) and estimate changes in strength that are directly
associated with changes in the bone compartments.(35,36)
To gain further insight into the observed clinical efficacy of
denosumab in reducing the risk of hip and spine fractures, in a
subset of subjects in the FREEDOM study, we applied FEA to the
hip and spine QCT scans to noninvasively assess changes in hip
and spine strength associated with denosumab treatment over
36 months.
Materials and Methods
Study design and participants
FREEDOM was an international, randomized, placebo‐controlled
study in postmenopausal women with osteoporosis.(5) Partic-
ipants received placebo or denosumab 60mg subcutaneously
every 6months for 36months, with daily supplements of calcium
(1000mg) and vitamin D (400 IU). Postmenopausal women
aged between 60 and 90 years with a BMD T‐score of <2.5 at
the lumbar spine and/or total hip, and not <–4.0 at either site,
were included in the study. Women were excluded if they had
any severe or >2 moderate vertebral fractures, conditions that
affected bone metabolism, or had taken oral bisphosphonates
for 36 months. Women were eligible if they had taken oral
bisphosphonates for36monthsbut noneduring the 12months
preceding enrollment into the study. Study centers in the
FREEDOM study, with expertise and access to a qualified scanner,
invited subjects to participate in a substudy of the hip and
lumbar spine QCT measurements. Calibration issues and
unavailability of analyzable scans at different time points limited
the analyses to 99 subjects (n¼ 48 placebo; n¼ 51 denosumab).
The protocol was approved by an independent ethics
committee or institutional review board at each study site.
Details of the methods and main results of the FREEDOM study
have been reported previously.(5)
Assessments
The QCT methodology used to assess BMD and geometric
parameters of the total hip and lumbar spine using whole‐body
scanners at selected study centers has been described
previously, as has the main BMD analysis.(37) Scans were
performed at 120 kV with a pitch of 1 using 170 mAs in the
hip and 100mAs in the spine, and reconstructed using amedium
kernel and a field of view of 400mm in the hip and 360mm in the
spine. The reconstructed slice thickness was 1.25mm. Scans
were obtained at baseline, 12, 24, and 36 months, and covered
1 cm above the femoral head to 2 cm below the lesser trochanter
for the hip assessment, or both L1 and L2 vertebrae for the spine
assessment. Scanner calibration and stability were assessed and
documented by Synarc (Portland, OR, USA, and Hamburg,
Germany) circulating a European Spine Phantom (ESP).
All image processing and image analysis for FEA assessments
were performed blinded to treatment, by O.N. Diagnostics
(Berkeley, CA, USA), as described elsewhere.(19,25,26,28) Briefly, the
QCT images were calibrated, segmented, and converted into
finite element models (40,000 elements per model), using
cube‐shaped, eight‐noded brick elements (1.5 mm‐sided for the
hip and 1.0mm‐sided for the spine). Because delineating the true
cortical envelope is difficult from clinical‐resolution CT scans,
particularly where the cortex is thin, we defined a “cortical”
compartment to include all obvious cortical bone (defined as
bone having an apparent BMD of >1.0 g/cm3) plus any other
bone within a fixed distance of the periosteal surface (3mm for
the hip; 2mm for the spine); the trabecular compartment was
defined as all remaining trabecular bone (Fig. 1). Element‐specific
Fig. 1. Example of finite element models for one subject at baseline. The
full three‐dimensional model is shown, with a schematic of how the loads
are applied (through center of head at hip; distributed evenly for spine).
The models for estimating strength changes associated with changes in
only the trabecular and “cortical” compartments are also shown (thin 2D
sections only). Our definition of the “cortical” compartment included all
obvious cortical bone (defined as bone having an apparent BMD of
>1.0 g/cm3) plus any other bone within a fixed distance of the periosteal
surface (3mm for the hip; 2mm for the spine); the trabecular
compartment was defined as all of the remaining trabecular bone.
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elastic properties (isotropic for the hip; anisotropic for the spine)
and elastic‐plastic failure properties were all derived from the
calibrated volumetric BMD values, using validated empirical
relations, and (for the hip) using higher strengths in compression
than tension.(38–40) After registering each bone to its baseline
configuration, boundary conditions were applied to simulate a
severe, unprotected fall to the side of the hip, with the diaphysis
angled at 15° with respect to the ground and 15° of internal
rotation. Femoral strength was defined from the resulting
nonlinear force‐strain curve of the whole femur as the force at
4.0% strain. For the spine, a similar approachwas taken inwhich a
thin layer of plastic was applied over each endplate through
which the vertebral body was loaded to simulated failure in
uniform compression. Spine strength was defined from the
resulting nonlinear force‐strain curve of thewhole vertebral body
as the force at 1.9% strain. For both hip and spine, these
implementations have been shown to provide excellent
correlations with measured strength from biomechanical
cadaver experiments with a Y¼ X type of absolute agreement
between model and experiment.(16,19,41)
We also performed controlled variations of these models to
provide additional strength outcomes, including trabecular and
“cortical” strengths (Fig. 1). Hip trabecular strength was
computed by turning all the bone in the “cortical” compartment
at each time point into plastic (a stiffer plastic for the compact
cortical bone and a less stiff plastic for the adjacent trabecular
bone) and then virtually reloading the resulting model to failure
as described above for the intact femur. Likewise, hip “cortical”
strength was computed by turning all the bone in the trabecular
compartment into (a low‐stiffness) plastic and then virtually
reloading to failure,(26) and spine trabecular strength was
computed by virtually removing the outer 2mm of bone and
then virtually reloading to failure.(32) Because a spine model
comprised only of a thin shell of cortical bone would be prone to
buckling if virtually loaded to failure, which would have
questionable relevance, spine “cortical” strength was calculated
as the overall spine strengthminus the spine trabecular strength.
We note that these trabecular and “cortical” strengths were
additive for the spine but not for the hip; this is because of the
complex nonparallel load transfer paths in the hip between the
trabecular and “cortical” compartments, both of which were
present in all hip models.
Statistical analysis
Subjects having both a baseline and1 post‐baseline FEA result
were included in the analysis. There was no imputation of
missing data. The percentage and absolute changes from
baseline in hip and spine strength were analyzed using an
analysis of covariance (ANCOVA) model including treatment and
adjusting for baseline value and age strata (stratification factor).
Least‐squares means and 95% confidence intervals (CIs) for each
treatment and for the treatment difference (denosumab –
placebo) at each time point were generated. All analyses were
exploratory and post‐hoc. The p values and CIs were not adjusted
for multiplicity.
Results
The baseline characteristics in this subset of women from the
FREEDOM study (Table 1) were similar to those reported for the
overall study population.(5) Mean age was 74.1 years in the
placebo group and 73.3 years in the denosumab group. Mean
total hip dual‐energy X‐ray absorptiometry (DXA) T‐score was
–2.0 and –1.7 in the placebo and denosumab groups,
respectively, and –2.8 at the lumbar spine in both treatment
groups.
For the women treated with denosumab, hip strength as
estimated by FEA increased significantly compared with baseline
by 5.3% at 12 months (p< 0.0001) and progressively over time,
reaching 8.6% at 36 months (p< 0.0001 compared with baseline
and 12months) (Fig. 2A). By contrast, for the women treated with
placebo, hip strength did not change at 12 months and
decreased thereafter to 5.6% by 36 months compared with
baseline (p< 0.0001). At 36 months, hip strength for the
denosumab group increased by 14.3% compared with placebo
(p< 0.0001). Similar changes occurred at the spine, but the
increases in strength were larger. From baseline, spine strength
increased by 18.2% (p< 0.0001) for the denosumab group and
decreased by –4.2% (p¼ 0.002) for the placebo group at
36 months (Fig. 2B), corresponding to a relative increase in
spine strength for the denosumab group of 22.4% compared
with placebo (p< 0.0001). The corresponding absolute changes
in strength at the hip and spine were also significantly higher for
the denosumab group compared with baseline and the placebo
group (p 0.0001 for all). At 36 months, mean absolute change
frombaseline in estimated hip strengthwasþ196 Newtons (N) in
the denosumab group compared with –123N in the placebo
group (p< 0.0001). At the spine, strength increased byþ513N in
the denosumab group compared with a decrease of –127N in
the placebo group.
Further analysis of the finite element models revealed
increases in strength associated with changes in both the
trabecular and “cortical” bone compartments in the denosumab
group for both the hip and spine (Fig. 3). By contrast, in the
placebo group, the hip and spine strength associated with
the trabecular compartment preferentially decreased from
baseline through 36 months, whereas the strength associated
with the “cortical” compartment was preserved.
For individual subjects at 36 months, changes in hip strength
were significantly, but weakly, correlated with changes in spine
strength for the denosumab group (r¼ 0.38; p¼ 0.02) but not for
the placebo group (r¼ 0.18; p¼ 0.39) (Fig. 4). At 36months, spine
strength increased in all denosumab‐treated subjects and hip
strength increased in all but two subjects, whereas both the hip
and spine strength decreased for themajority of placebo‐treated
subjects.
Table 1. Baseline Characteristics
Placebo
n¼ 48
Denosumab
n¼ 51
Age (years) 74.1 (6.0) 73.3 (4.2)
BMI (kg/m2) 25.7 (4.6) 26.3 (4.5)
Total hip QCT BMD (mg/cm3) 217 (31) 227 (34)
Lumbar spine (trabecular) QCT
BMD (mg/cm3)
64.5 (17.2) 69.6 (18.8)
Total hip BMD DXA T‐score –2.0 (0.8) –1.7 (0.9)
Lumbar spine BMD DXA T‐score –2.8 (0.7) –2.8 (0.5)
Total hip FEA strength (Newtons) 2273 (570) 2512 (686)
Total spine FEA strength (Newtons) 2841 (628) 2879 (583)
Values are means (standard deviations).
BMI¼body mass index; QCT¼quantitative computed tomography;
BMD¼bone mineral density; DXA¼dual‐energy X‐ray absorptiometry;
FEA¼ finite element analysis.
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Discussion
In providing estimates of how denosumab alters both hip and
spine strength compared with baseline and placebo, these
results offer insight into the mechanisms by which denosumab
reduces hip and spine fracture risk. The overall strength
improvements observed here—which were all derived from
FEA of the QCT scans and thus represent estimates of actual
changes in strength—were relatively large at both the hip and
spine, and substantiate the clinical relevance of the observed and
previously described gains in DXA BMD with denosumab
therapy, including the gains observed in the overall FREEDOM
study.(5,6,42) Indeed, the progressive increases in estimated
strength in response to denosumab treatment reported here
suggest that the continued gains in BMD from denosumab
treatment, previously reported in the phase 2 study for up to
8 years and up to 6 years in the FREEDOM extension study, are of
clinical consequence.(43,44) This finding is consistent with the
strong relationship reported by Austin and colleagues(45)
between DXA BMD gains and the documented fracture risk
reductions with denosumab treatment.
The improvements in estimated strength were associated with
positive changes in hip and spine strength of both the trabecular
and “cortical” compartments for those women treated with
denosumab. In our models, these changes in compartmental
strength can be influenced by changes in overall density and/or
volume of the compartments, although we did not assess
changes in volume. A recently published analysis of this QCT
cohort, using the Mindways software,(46) reported a significant
treatment effect on the volumes of both the trabecular
(decrease) and cortical (increase) compartments, but no volume
change related to the external geometry, suggesting an
endosteal shift of what was defined as trabecular to cortical
bone. This could be real or may be associated with assumptions
made in the trabecular–cortical segmentation by the Mindways
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software. In general, it is impossible to explicitly differentiate
trabecular from cortical bone from the resolution of the clinical
QCT scans used in this study. Thus, a more definitive assessment
of possible endosteal changes from trabecular to or from cortical
bone remains an ongoing topic of active research. However, the
finite element assessment in our study used a single continuous
volume‐averaged material property relation for the bone that
does not depend on any classification into trabecular or cortical
bone, and thus our finite element strength estimates are less
influenced by the spatial voxel classification. The changes in
trabecular and “cortical” strength, as computed for the hip,
involve highly idealized models in which either the trabecular or
“cortical” compartment, respectively, is homogenized across
subjects and over time. Results from those calculations, while
insightful, need to be interpreted carefully because those
homogenized compartments only reflect generic measures of
bone density.
The positive effect of denosumab on both the trabecular and
“cortical” compartments, reported in other studies of denosu-
mab versus placebo and versus alendronate,(47,48) may be the
result of denosumab’s ability to robustly diminish bone
resorption throughout the skeleton.(49) The substantial reduction
in bone resorption biomarkers,(7) which occurs to a greater
degree for denosumab than bisphosphonates,(50,51) reflects a
combination of rapidly arresting bone resorption and inhibiting
osteoclastic differentiation throughout the skeleton.(7,52) The
data in the current study confirm that these changes appear
robust across patients because improvements in strength from
baseline were observed in nearly all subjects treated with
denosumab. Further, the large effect of denosumab treatment
on the trabecular compartment directly reversed the significant
trabecular loss that occurred in the placebo group. These
findings suggest that for patients treated with calcium and
vitamin D only (placebo group), the trabecular bone is
continually being lost, and therefore, overall femoral strength
may eventually come to depend more on the remaining cortical
bone as it takes up more load from the weakened trabecular
compartment. If so, then the cortical bone might assume an
added biomechanical role in those individuals having the
greatest risk for hip fracture, as suggested by others,(53,54) and
improvements in the cortical compartment might therefore be
particularly beneficial under those conditions.
Our results may help explain the hip fracture efficacy observed
in FREEDOM.(5) In the present study, treatment with denosumab
produced a 14.3% strength effect at 36 months relative to the
effect in subjects treated with just calcium and vitamin D
(placebo group). Other analyses of the FREEDOM study have
reported an age‐related efficacy effect: Hip fracture reduction
increased from 40% in the overall cohort to 62% in subjects
75 years and older.(48,55) In general, the degree of fracture
efficacy of any treatment on fracture risk reduction in a clinical
trial depends on both the fracture risk of the population at
baseline as well as the effect of the treatment on the change in
overall bone strength. Biomechanically, for any individual
patient, there should be a threshold effect related to the critical
level of loading required to actually fracture a bone—external
forces below the threshold do not fracture the bone, whereas
forces above the threshold do, with little gray area between
(although that threshold force may vary across patients and with
fall conditions and is difficult to predict).(56)
Therefore, changes in strength in response to therapies might
need not only to be compared with placebo (for which strength
is expected to decline over time), but also and perhaps more
importantly, compared with baseline, with any possible
threshold effect potentially acting as an interaction effect
between these cohort and baseline factors. For example, the
further an individual subject is from their own fracture threshold
at the start of the study, the greater the strength improvement
needed to take that individual above the fracture threshold force
needed to prevent a fracture. These considerations imply that, in
a clinical drug trial, increases in strength from baseline should
improve fracture efficacy, and the larger the increase, the more
robust the efficacy—but the efficacy itself may depend on the
baseline level of strength, being greatest if the baseline strength,
on average, is close to this putative fracture threshold in the
majority of subjects. This mechanism could potentially explain
the age‐related hip efficacy observed in the FREEDOM trial. In this
way, interventions thatmerelymaintain strength are expected to
be better than no intervention at all and may be sufficient for
people in whom the risk for fracture is not in an elevated
category because such treatments would maintain strength at a
sufficient level to avoid a fracture with a fall or equivalent trauma.
However, actually improving strength may be necessary to
reduce fracture rates in people at elevated fracture risk,
particularly if their strength is low to start.(56)
There are limitations in our study. First, the small sample size
prevented assessment of the relationship between changes in
estimated strength and fracture outcomes at the subject level.
However, the larger FREEDOM trial, from which our sample was
derived, randomly assigned participants to denosumab treat-
ment or placebo, and the baseline characteristics were similar
between our sample and the overall FREEDOM cohort(5) and
were similar between treatment groups. Thus, it is reasonable to
assume that the general trends observed in the original
FREEDOM cohort would also apply to this substudy. Other
limitations relate to the methods used to assess changes in
strength. Although it is not possible to directly assess changes in
whole‐bone strength in living humans, FEA of clinical QCT scans
is arguably the best currently available noninvasive technique
that can be used in vivo in patients at both hip and spine
locations.(36) This technique has been validated by multiple
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independent research groups for the hip and spine in both
cadaver bone strength(8–16) and clinical fracture outcome
studies,(16–24) and it is an FDA‐approved approach that provides
an integrative outcome of whole‐bone strength that is intuitively
associated with the etiology of osteoporotic fractures. The
models have limited spatial resolution (1mm imaging voxels);
therefore, they cannot capture the bone microstructure,
including the trabecular microarchitecture, Haversian porosity,
any microstructure of the endosteal bone at the interface
between well‐defined cortical and trabecular bone, or the shell‐
type microstructure of the thin cortex around the femoral neck.
The limited spatial resolution also precludes accounting for
potential microscale effects of denosumab. For example, it has
been proposed that reducing bone turnover and inhibiting
“stress risers” may be an additional mechanism by which
antiresorptive therapies reduce fracture risk,(57,58) an effect that
would serve to further increase strength for the denosumab
group. Lastly, no adjustment was made for any possible changes
in the tissue‐level material properties resulting from treatment,
such as increased secondary mineralization. However, bio-
mechanical studies in adult ovariectomized cynomolgus mon-
keys treated with denosumab for 16 months have shown no
detectable biomechanical negative effects on tissue‐level
material properties.(59) Even so, results should be interpreted
with these limitations in mind.
In summary, denosumab administered subcutaneously at a
dose of 60mg every 6 months substantially improved FEA
estimates of hip and spine strength, both compared with
baseline and the administration of calcium and vitamin D only
over 36 months. These improvements were progressive over
time and were influenced by parallel positive estimated strength
changes in both the trabecular and “cortical” compartments.
These observations highlight the potential benefit of denosu-
mab to improve and reverse the negative consequence of
postmenopausal‐ and aging‐induced skeletal decay on strength,
and to markedly reduce fracture incidence in subjects at
increased or high risk for hip and spine fractures.
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